Public Comment: Optimizing FDA’s Use of and Processes for Advisory Committees

To request access to this content please complete the form below.

3D Communications’ Co-Founder, Jim DiBiasi, provided public comment on the issues of voting questions and ways to improve advisory committee meetings at a recent FDA listening session.

In his comments, Jim highlights the significant unintended consequences that can occur with not voting on at least the question of benefit-risk. He also discusses a few important changes to advisory committees that may be helpful to maintaining a rigorous vetting of data while providing useful information to the FDA and to the public.

Register above to receive a recording of the session.

  • Share On

How Can We Help You?

Get Started